Acute and chronic postoperative pain and functional disability persisted among patients who underwent posterior spinal fusion despite multimodal analgesic management.

The suzetrigine, which only acts on pain neurons, is the first innovation in analgesia in the last 20 years. "It stands out ...

Meet suzetrigine, a non-opioid that promises to avoid addiction risk. But some experts say it can't replace opioids ...

Unlike opium, nitazenes and other synthetic opioids can be produced anywhere in the world using precursor chemicals that are often uncontrolled.

If the attention generated by BioSpace’s coverage of this landmark approval is any indication, Americans are hungry for ...

Most states allow some form of "medical marijuana." It is especially popular with pain patients, many of whom do not have ...

Dr. Sanjay Gupta said Tuesday that the approval of a new non-opioid pain medication is “a pretty big deal.” “This is a pretty ...

There is a paucity of safe, efficacious non-opioid analgesic treatments for chronic pain ... the Company is progressing these programs toward Investigational New Drug, ("IND"), filings and ...

Federal officials on Thursday approved a new type of pain pill designed to eliminate the risks of addiction and overdose ...

Introducing Journavx: the FDA-approved non-opioid, non-addictive drug for acute pain. A major breakthrough in pain medication ...

The U.S. Food and Drug Administration (FDA) approved Journavx (suzetrigine) oral tablets on Thursday as a first-in-class non-opioid analgesic to treat acute pain in adults. “Today’s approval is an ...

The U.S. Food and Drug Administration (FDA) approved Journavx (suzetrigine) oral tablets on Thursday as a first-in-class non-opioid analgesic to treat acute pain in adults. The new development is ...